{"disease":{"id":"hepatic-porphyria","name":"Hepatic porphyria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"givosiran","indication_name":"Hepatic porphyria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Givlaari","generic_name":"GIVOSIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"aminolevulinate synthase1 (ALAS1) mRNA","drug_class":"Aminolevulinate Synthase 1-directed RNA Interaction","quality_score":70,"revenue":"400","mechanism":"Givlaari works by binding to and silencing the messenger RNA (mRNA) that produces the enzyme aminolevulinate synthase 1 (ALAS1), which is overproduced in patients with hepatic porphyria."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03547297","title":"INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP","phase":"","overall_status":"TERMINATED","enrollment_count":212,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04923516","title":"Prevalence of Acute Hepatic Porphyria","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Association pour la Recherche en Medecine Interne","has_results":false},{"nct_id":"NCT04883905","title":"ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03338816","title":"ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT05344599","title":"Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT03505853","title":"A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04056481","title":"Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}